Aaron Dotson1, Allison May1, Facundo Davaro1, Syed Johar Raza1, Sameer Siddiqui1, Zachary Hamilton2. 1. Division of Urology, Department of Surgery, Saint Louis University, 3635 Vista Ave, 3rd Floor Desloge Towers, St. Louis, MO, 63110, USA. 2. Division of Urology, Department of Surgery, Saint Louis University, 3635 Vista Ave, 3rd Floor Desloge Towers, St. Louis, MO, 63110, USA. zachary.hamilton@health.slu.edu.
Abstract
BACKGROUND: Squamous cell carcinoma (SCC) of the bladder is a rare, aggressive malignancy. Unlike urothelial cell carcinoma, SCC is resistant to chemotherapy and guidelines recommend radical cystectomy (RC) without neoadjuvant chemotherapy (NAC). We aimed to evaluate the current management and survival of patients with invasive SCC treated with or without NAC. METHODS: 671 patients with invasive SCC bladder cancer from 2004 to 2015 in the National Cancer Data Base were identified. Patients were stratified by treatment with RC alone or NAC prior to RC (NAC + RC). Survival analysis was performed with Kaplan-Meier and Cox regression. Secondary outcomes included length of stay and readmission. RESULTS: Of 671 patients, 92.8% were treated with RC alone and 7.2% with NAC + RC. Cox regression for mortality was performed including age, Charlson score, clinical stage, and NAC. Increased risk of mortality was noted with increasing age (OR 1.01, p = 0.023) and Charlson score of 1-3 (HR 1.58-1.68, p < 0.05). NAC did not confer survival advantage (HR 1.17, p = 0.46). On Kaplan-Meier analysis, the overall survival was equivalent (log-rank p = 0.804). Hospital stay and readmission were similar between RC and NAC + RC groups. CONCLUSIONS: Analysis of a national tumor registry suggests a lack of overall survival benefit for NAC with localized, muscle invasive SCC of the bladder. Further research directed at chemotherapy regimens for SCC is needed to optimize treatment and improve survival outcomes.
BACKGROUND:Squamous cell carcinoma (SCC) of the bladder is a rare, aggressive malignancy. Unlike urothelial cell carcinoma, SCC is resistant to chemotherapy and guidelines recommend radical cystectomy (RC) without neoadjuvant chemotherapy (NAC). We aimed to evaluate the current management and survival of patients with invasive SCC treated with or without NAC. METHODS: 671 patients with invasive SCC bladder cancer from 2004 to 2015 in the National Cancer Data Base were identified. Patients were stratified by treatment with RC alone or NAC prior to RC (NAC + RC). Survival analysis was performed with Kaplan-Meier and Cox regression. Secondary outcomes included length of stay and readmission. RESULTS: Of 671 patients, 92.8% were treated with RC alone and 7.2% with NAC + RC. Cox regression for mortality was performed including age, Charlson score, clinical stage, and NAC. Increased risk of mortality was noted with increasing age (OR 1.01, p = 0.023) and Charlson score of 1-3 (HR 1.58-1.68, p < 0.05). NAC did not confer survival advantage (HR 1.17, p = 0.46). On Kaplan-Meier analysis, the overall survival was equivalent (log-rank p = 0.804). Hospital stay and readmission were similar between RC and NAC + RC groups. CONCLUSIONS: Analysis of a national tumor registry suggests a lack of overall survival benefit for NAC with localized, muscle invasive SCC of the bladder. Further research directed at chemotherapy regimens for SCC is needed to optimize treatment and improve survival outcomes.
Entities:
Keywords:
Bladder cancer; Cystectomy; Neoplasm invasion; Squamous cell cancer
Authors: H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2003-08-28 Impact factor: 91.245
Authors: Wassim Kassouf; Philippe E Spiess; Arlene Siefker-Radtke; David Swanson; H Barton Grossman; Ashish M Kamat; Mark F Munsell; Charles C Guo; Bogdan A Czerniak; Colin P Dinney Journal: Cancer Date: 2007-08-15 Impact factor: 6.860
Authors: Nikolaj Lagwinski; Anil Thomas; Andrew J Stephenson; Steven Campbell; Aaron P Hoschar; Ehab El-Gabry; Robert Dreicer; Donna E Hansel Journal: Am J Surg Pathol Date: 2007-12 Impact factor: 6.394
Authors: Stefania Zamboni; Luca Afferi; Francesco Soria; Atiqullah Aziz; Mohammad Abufaraj; Cedric Poyet; Andrea Necchi; David D'Andrea; Giuseppe Simone; Mariaconsiglia Ferriero; Ettore Di Trapani; Claudio Simeone; Alessandro Antonelli; Andrea Gallina; Francesco Montorsi; Alberto Briganti; Renzo Colombo; Giorgio Gandaglia; Agostino Mattei; Philipp Baumeister; Livio Mordasini; Kees Hendricksen; Charlotte S Voskuilen; Michael Rink; Shahrokh F Shariat; Evanguelous Xylinas; Marco Moschini Journal: World J Urol Date: 2020-07-25 Impact factor: 4.226
Authors: Giuseppe Rosiello; Angela Pecoraro; Carlotta Palumbo; Sophie Knipper; Stefano Luzzago; Marina Deuker; Zhe Tian; Giorgio Gandaglia; Nicola Fossati; Francesco Montorsi; Shahrokh F Shariat; Fred Saad; Alberto Briganti; Pierre I Karakiewicz Journal: World J Urol Date: 2020-05-18 Impact factor: 4.226
Authors: Carolyn D Hurst; Guo Cheng; Fiona M Platt; Olivia Alder; Emma Vi Black; Julie E Burns; Joanne Brown; Sunjay Jain; Jo-An Roulson; Margaret A Knowles Journal: J Pathol Clin Res Date: 2022-03-14
Authors: Mario Alvarez-Maestro; Francesco Chierigo; Guglielmo Mantica; J M Quesada-Olarte; D M Carrion; Juan Gomez-Rivas; Alvaro Pinto-Marin; Alfredo Aguilera Bazan; Luis Martinez-Piñeiro Journal: Arab J Urol Date: 2021-11-07